Osivax Secures Major BARDA Funding for Vaccine Development
Osivax, a biopharmaceutical company specializing in the advance of novel vaccines, has recently announced a significant milestone in its quest to innovate influenza prevention. With a newly acquired funding of $19.5 million from the Biomedical Advanced Research and Development Authority (BARDA), Osivax is poised to propel its broad-spectrum influenza A vaccine candidate, OVX836, into the next phase of development.
Accelerating Development of OVX836
Key players in public health recognize the importance of preparedness in the face of seasonal and pandemic influenza outbreaks. Osivax is leveraging this funding to accelerate the clinical development of OVX836. This next-generation vaccine is designed to offer robust protection against not only existing influenza A strains but also emerging variants, thereby allowing for a more universal response to influenza threats.
CEO's Vision and Future Trial Preparations
"Osivax is excited to explore our universal flu vaccine approach and the potential of OVX836 to transform global influenza preparedness," highlighted Alexandre Le Vert, CEO and Co-Founder of Osivax. This funding will facilitate comprehensive preparations for large-scale efficacy trials, vital for validating the vaccine's effectiveness in real-world applications.
Funding Breakdown and Strategic Initiatives
The financial package includes an allocation of $11.5 million specifically for the continued development and optimization of OVX836, along with an additional $8 million earmarked for establishing a large-scale efficacy study. With a clear route mapped for subsequent trials, the agreement outlines options for further financial support, potentially funding a Phase 2b trial and activities related to the scale-up of manufacturing processes.
Importance of Broadly Protective Vaccines
As global health challenges evolve, the need for vaccinations that offer widespread protection becomes increasingly crucial. Osivax’s OVX836 is notable for its unique targeting of the nucleoprotein of the influenza virus—a highly conserved internal component that exhibits much lower mutation rates compared to traditional vaccine targets. This innovative approach could be key to developing a truly universal vaccine that defends against a wide range of influenza variants.
Innovative Technology Behind OVX836
OVX836 represents a breakthrough in vaccination technology. Utilizing Osivax’s oligoDOM technology, this candidate vaccine consists of a recombinant version of the nucleoprotein (NP) that self-assembles into nanoparticles. This mechanism is designed to elicit a strong immune response, activating both T-cell and B-cell immunity more effectively than traditional vaccines. To date, OVX836 has been evaluated in seven clinical trials involving over 1,400 participants, demonstrating promising safety and immunogenicity outcomes.
The Vision for a Pan-Respiratory Virus Vaccine
Osivax is steadfast in its ambition to expand beyond influenza. The company aims to develop vaccines capable of combating various respiratory viruses, leveraging the strengths of its innovative platform technology. The success of OVX836 could serve as a foundation for addressing additional infectious disease challenges in collaboration with global health initiatives.
Contact and Further Information
For more details about Osivax and its pioneering work in vaccine development, visit www.osivax.com. For direct inquiries, you can reach out to Alexandre LE VERT, CEO, via email at contact@osivax.com or call +33 (0)9 70 30 13 80.
Frequently Asked Questions
What is Osivax’s main focus?
Osivax focuses on developing vaccines that offer broad protection against highly mutable viruses, emphasizing influenza and respiratory viruses.
What is the significance of the BARDA funding?
The $19.5 million funding from BARDA will accelerate the development of OVX836, preparing for large-scale efficacy trials and enhancing production capabilities.
How does OVX836 differ from traditional influenza vaccines?
OVX836 targets the conserved nucleoprotein of the influenza virus, providing a potentially wider defensive range against various strains compared to traditional vaccines that target surface antigens.
What stage is OVX836 currently in?
OVX836 is currently in Phase 2 clinical trials, with a positive outlook based on prior safety and immunogenicity evaluations.
What is Osivax’s long-term vision?
Osivax aims to develop a pan-respiratory virus vaccine that can protect against multiple viral strains, expanding its impact in vaccine technology.
